The Life Sciences Report

Cash-Rich Zynerba's Synthetic Cannabinoid Product Line Ready to Rumble
Source: The Life Sciences Report  (4/5/17)
Zynerba Pharmaceuticals specializes in developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Devon, Pennsylvania-based company's Q4/16 financial results disclose a substantial cash kitty of ~$78M available to fund its pipeline of medical marijuana products, ZYN001 and ZYN002. More >

3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab
Source: The Life Sciences Report  (3/30/17)
With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form. More >

Many Paths to Success with DURECT's Pipeline
Source: Dr. James Brown for The Life Sciences Report  (3/29/17)
DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology. More >

Therapix IPO on NASDAQ Could Catapult It into the Big Leagues
Source: The Life Sciences Report  (3/21/17)
Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs. More >

RepliCel's Phase 1 Trial for Hair Loss Completed Successfully
Source: The Life Sciences Report  (3/16/17)
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. More >

3D Signatures' Disruptive Technology Moving Ahead for Prostate Cancer and Hodgkin's Lymphoma
Source: The Life Sciences Report  (3/8/17)
3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests. More >

Major Funds Betting On Trump Sector
Source: Tom Beck for The Life Sciences Report  (2/25/17)
Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global. More >

Buckle Up: Inflation at 58-Month High
Source: Lior Gantz for The Gold Report  (2/23/17)
The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena. More >

RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report  (2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >

Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth
Source: The Life Sciences Report  (2/22/17)
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. More >

Investing in Life Sciences Under the Trump Presidency
Source: Kristin McFarland for The Life Sciences Report  (2/16/17)
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. More >

Regeneus Hits the Fast Track with Major Japanese Partnership
Source: The Life Sciences Report  (2/8/17)
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. More >

Luminor Drives the Scout DS Forward
Source: Bob Moriarty for The Life Sciences Report  (2/6/17)
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. More >

The Future of Cannabis Investing
Source: Tom Beck for Streetwise Reports  (2/3/17)
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global. More >

ContraVir's Hep B Drug Could Be a Game Changer
Source: The Life Sciences Report  (2/1/17)
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company. More >

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report  (2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >

Inovio's Zika Vaccine Generates Robust Immune Responses
Source: The Life Sciences Report  (1/25/17)
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. More >

2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Source: The Life Sciences Report  (1/18/17)
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. More >

Time to Go Long on BrainStorm Cell Therapeutics?
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report  (1/16/17)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. More >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Source: The Life Sciences Report  (1/3/17)
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. More >

Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries
Source: The Life Sciences Report  (12/21/16)
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. More >

VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
Source: The Life Sciences Report  (12/21/16)
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. More >

Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth
Source: The Life Sciences Report  (12/14/16)
3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements.
More >

Why the Canadian Marijuana Sector Is the Next Big Thing and Why Emblem Is Our Top Pick
Source: Gecko Research for Streetwise Reports  (12/8/16)
Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp., which begins trading on the TSX.V on Dec. 12 under the symbol EMC, is their top pick. More >

Reliq Health Technologies Pilots Remote Patient Monitoring Program
Source: The Life Sciences Report  (12/7/16)
Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology. More >